R-A Lavergne1,2, F Morio1,2, I Danner-Boucher3, D Horeau-Langlard3, V David4, F Hagen5,6, J F Meis5,7, P Le Pape1,2. 1. Parasitology and Medical Mycology Laboratory, Nantes University Hospital, Nantes, France. 2. Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2, Nantes, France. 3. Department of Pulmonology, Cystic Fibrosis Reference Centre, Nantes University Hospital, Nantes, France. 4. Department of Paediatrics, Nantes University Hospital, Nantes, France. 5. Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. 6. Department of Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands. 7. Centre of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Studies on Aspergillus fumigatus azole resistance in cystic fibrosis patients are scarce despite the fact that it is the most frequently isolated fungus from respiratory samples from these individuals. OBJECTIVES: To evaluate resistance prevalence, investigate mechanisms of resistance and explore the relationship between resistant isolates by genotyping. METHODS: We conducted a prospective 1 year study (from 1 January to 31 December 2015), based on the investigation of up to five colonies per sample from cystic fibrosis patients. RESULTS: Twenty-three (6.5%) isolates among the 355 tested were resistant to at least one triazole drug, using the EUCAST reference method, leading to a prevalence of 6.8% (6/88 patients). Analysis of resistance mechanisms highlighted TR34/L98H (n = 10), TR46/Y121F/T289A (n = 1), WT cyp51A (n = 11) and F46Y/M172V/N248T/D255E/E427K (n = 1). No genotype was shared between patients. CONCLUSIONS: This study showed a relatively stable resistance prevalence in comparison with the previous study conducted in 2010-11 (8%), although resistance mechanisms varied between the two studies.
BACKGROUND: Studies on Aspergillus fumigatusazole resistance in cystic fibrosispatients are scarce despite the fact that it is the most frequently isolated fungus from respiratory samples from these individuals. OBJECTIVES: To evaluate resistance prevalence, investigate mechanisms of resistance and explore the relationship between resistant isolates by genotyping. METHODS: We conducted a prospective 1 year study (from 1 January to 31 December 2015), based on the investigation of up to five colonies per sample from cystic fibrosispatients. RESULTS: Twenty-three (6.5%) isolates among the 355 tested were resistant to at least one triazole drug, using the EUCAST reference method, leading to a prevalence of 6.8% (6/88 patients). Analysis of resistance mechanisms highlighted TR34/L98H (n = 10), TR46/Y121F/T289A (n = 1), WT cyp51A (n = 11) and F46Y/M172V/N248T/D255E/E427K (n = 1). No genotype was shared between patients. CONCLUSIONS: This study showed a relatively stable resistance prevalence in comparison with the previous study conducted in 2010-11 (8%), although resistance mechanisms varied between the two studies.
Authors: Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup Journal: J Antimicrob Chemother Date: 2022-07-28 Impact factor: 5.758